ARTH
$0.05
Arch Therapeutics
$.00
(1.09%)
ARTH
Earnings Whisper ®
N/A
3rd Quarter June 2022
Consensus:  ($0.01)
Revenue:  $0.96 Mil
Friday
Aug 26
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ARTH reports earnings?
Beat
Meet
Miss

Where is ARTH's stock price going from here?
Up
Flat
Down
Stock chart of ARTH
Analysts
Summary of analysts' recommendations for ARTH
Score
Grade
Pivots
Resistance
$0.06
$0.05
$0.05

$0.04

Support
$0.04
$0.04
$0.03
Tweet
Growth
Description
Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts.
Peers
Stryker3MBoston ScientificAbbottBecton, DickinsonBaxter InternationalTeleflexResMedWatersIntegra LifeSciences Holdings